Clinical Efficiency

Paxlovid for COVID-19: New Prescription Protocol

June 30, 2022

Paxlovid for COVID-19: New Prescription Protocol

We are excited to announce that providers can use Zipnosis to more efficiently prescribe Pfizer’s Paxlovid and help COVID-positive patients feel better faster. We’ve added prescription for Paxlovid to our suite of protocols that enable providers to treat patients in as little as 89 seconds for 400+ unique diagnoses.

Prescribe Paxlovid for COVID-19 with asynchronous telemedicine

Our Prescription for Paxlovid protocol leverages Zipnosis’ asynchronous telemedicine platform to streamline patient symptom intake, diagnosis, and treatment. The platform’s intelligent adaptive interviews mimic the questions a provider might ask a patient during a consultation – but without the burden of manually collecting data and inputting it into an EMR. Each time the patient answers a question, the subsequent questions adjust to collect more information on symptoms. At the end of the interview, providers receive a detailed SOAP note with a suggested diagnosis and prescription. Learn more with our Definitive Guide to Async

Patients will answer questions that include but are not limited to results of the COVID-19 test, symptoms, the duration of symptoms, past medical history, renal and liver function, pregnancy, and breastfeeding. Patients can upload the results of their COVID-19 test, which is optional.

Which patients are eligible to receive Paxlovid for COVID-19?

Adult patients with confirmed COVID-19 who have experienced mild to moderate symptoms within the last five days may be eligible for prescription Paxlovid through this clinical protocol. Patients with complications or severe symptoms will be referred from the protocol to an appropriate level of care. 

Both standard and renal impairment dosing of Paxlovid is available for patients. Patients will also receive educational information on the appropriate use of medication, follow-up care, and links to CDC and FDA Paxlovid patient fact sheet.  

We constantly add new protocols to our asynchronous telemedicine platform 

All our clinical protocols are built based on evidence-based guidelines, such as those from the Centers for Disease Control and Prevention (CDC), Infectious Disease Society (IDSA), U.S. Food and Drug Administration (FDA), and others. The protocols are also reviewed regularly by our team of clinical experts, our esteemed Clinical Quality Advisory Council (CQAC), and the CQAC Pediatric Sub-committee group. The CQAC is a group of health system clinical experts across the country who provides leading-edge direction and feedback on our virtual care solution and clinical protocols.  

Paxlovid: Pfizer’s antiviral medication for treating COVID-19

As a reminder, Paxlovid is an investigational medicine that is only authorized under emergency use by FDA. As such, it may have side effects that are not yet known. As COVID-19 is still widespread and continued research is going on, we will continue to update the protocol with any new antivirals as they are developed and expected. If patients have symptoms but get a negative COVID-19 test or are unsure if it is COVID-19, they can also start a visit for “Cold, Sinus Infection, or Influenza (Flu)” and get evaluated by a clinician.  

For more detailed information on Paxlovid, please refer to this fact sheet from FDA. For the latest updates on COVID-19, please visit the Centers for Disease Control and Prevention.  

Let’s continue doing what we need to do to stay safe and keep others safe.   

Stay Safe! Stay Healthy!


Asynchronous Care

Asynchronous Telemedicine Guide + COVID-19: The Largest Case Study on Async

When we built this guide, we set out to create a single comprehensive resource for everything healthcare professionals will ever need to know about asynchronous telemedicine. It’s 29 pages of pure data, research, and the largest case study ever conducted on async. 

Case Study

Gain capacity to care

Maximize clinical capacity, reduce administrative burden, expand access, and increase patient satisfaction.